Incyte Corp. (INCY)

Company Description

Incyte Corporation (Wilmington, Delaware) is a biopharmaceutical company that is focused on developing novel small molecule therapies for the treatments of cancers and inflammatory diseases. The company obtained approval in the U.S. for Jakafi in late 2011, which is a first-in class compound for myeloproliferative disorders that inhibits the intraceullar Janus kinases (Jak) signaling pathway; the ex-U.S. ruxolitinib rights have been licensed to Novartis in a deal potentially valued at up to $1 billion. INCY’s second key pipeline product is INCB28050, which is a second-generation oral Jak inhibitor in development for autoimmune disorders such as rheumatoid arthritis. The company has licensed global rights to INCB28050 to Lilly, and plans to co-develop the agent in rheumatoid arthritis. Behind ruxolitinib and INCB28050, INCY has several earlierstage Phase I/II oncology assets, which have different mechanisms of action, and a fully owned second generation Jakafi.


Route 141 & Henry Clay Road
Wilmington, DE 19880
United States



Get BioInvest's perspective on Incyte's CEO

Latest Company News

What Story Are The Numbers Telling For Incyte Corporation (NasdaqGS:INCY) Clayton News - 5 hours ago Incyte Corporation (NasdaqGS:INCY) presently has a current ratio of 3.04. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities ... [...]
Fri, Aug 18, 2017 11:34:00 PM, Continue reading at the source
Looking For a Catalyst: Updates on Incyte Corporation (NASDAQ:INCY) and Equity ... FLBC News - 7 hours ago Bargain stock hunters have honed in their attention of late on shares of Incyte Corporation (NASDAQ:INCY). The stock is currently valued at $121.19 after moving -0.34% in the most recent session and -2.34% over the past 5 trading days. Incyte Corporation - Receive News & Ratings Daily - BBNS Incyte Corporation (INCY) Lowered to “Hold” at BidaskClub - Markets Daily [...]
Fri, Aug 18, 2017 9:22:00 PM, Continue reading at the source
Major Analyst Actions Under Review: Incyte Corporation (INCY), Array BioPharma ... Post Analyst - 11 hours ago The recently concluded session had traders exchanging Incyte Corporation (NASDAQ:INCY) low level. Roughly 1 million shares changed hands compared to the three-month volume average 1.58 million shares. [...]
Fri, Aug 18, 2017 5:37:00 PM, Continue reading at the source
Incyte Corporation (INCY) Ownership Decreased by Manufacturers Life Insurance ... Modern Readers - Aug 17, 2017 Manufacturers Life Insurance Company, The sold 33,622 shares in quarter ending 06/30/2017 decreasing its exposure to Incyte Corporation by 43.9%. Its position was valued at $5,404,000 a decrease of 47.2% as of the end of the quarter. Other firms have ... Incyte Corporation (NASDAQ:INCY) EVP Sells $850118.65 in Stock - ExpressNewsline Incyte Corporation (NASDAQ:INCY) Earns Coverage Optimism Rating of 0.10 - BNB Daily (blog) [...]
Thu, Aug 17, 2017 9:22:00 PM, Continue reading at the source
New York State Teachers Retirement System Adjusts Its Investment in Incyte ... Modern Readers - Aug 11, 2017 New York State Teachers Retirement System reports that it bought 3,417 shares in the previous quarter increasing its stake in Incyte Corporation (INCY) by 1.3%. Its stake stood at $32,369,000 a decrease of $1,538,000 as of the end of the quarter. These ... Investors are upbeat on the prospect of these stock's: Incyte Corporation ... - StockNewsJournal Incyte Corporation (INCY) Daily Technical Review & Outlook - StockNewsGazette [...]
Fri, Aug 11, 2017 5:56:00 PM, Continue reading at the source
Forbes Magazine Names Incyte One of the World's Most Innovative Companies for ... Business Wire (press release) - Aug 10, 2017 WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 6th on Forbes magazine's 2017 list of the World's Most Innovative Companies. [...]
Thu, Aug 10, 2017 12:45:00 PM, Continue reading at the source
Incyte Corporation Using Put Spreads to Outperform the Stock CML News - Aug 10, 2017 Selling puts is a common option strategy during a bull market, but it turns out that looking at a lower risk put spread, and being rather clever in how we treat earnings, yields powerful results in Incyte Corporation (NASDAQ:INCY) . More urgently, if ... [...]
Thu, Aug 10, 2017 6:00:00 AM, Continue reading at the source
Right After Earnings, The Intelligent Options Trade in Incyte Corporation CML News - Aug 4, 2017 For Incyte Corporation, irrespective of whether the earnings move was up or down, if we waited two calendar days after the stock move, and then sold a one-month out of the money put spread, the results were simply staggering. [...]
Fri, Aug 04, 2017 9:45:00 PM, Continue reading at the source
Incyte Corporation (INCY) Shares Drop on Q2 Loss - Aug 1, 2017 Incyte Corporation (INCY) The pharmaceutical company unveiled earnings at a loss of six cents per share, wider than analysts' expectations of a loss of three cents per share. Incyte reports second-quarter loss despite strong revenue - Delaware Business Times Incyte (INCY) Q2 2017 Results - Earnings Call Transcript - Seeking Alpha [...]
Tue, Aug 01, 2017 3:33:00 PM, Continue reading at the source
Lilly and Incyte Provide Update on Baricitinib PR Newswire (press release) - Jul 25, 2017 INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that a resubmission to the U.S. [...]
Tue, Jul 25, 2017 10:07:00 AM, Continue reading at the source